TABLE 3.

Clinical trials on OAds in combination with immune checkpoint inhibitors.

OAd name	Transgene	Combination therapy	Indication	Trial number	Phase
ONCOS-102 (Ad5/3-D24-GM-CSF)	GM-CSF	Pembrolizumab, cyclophosphamide	Melanoma	NCT03003676	I
		Durvalumab	Colorectal cancer, ovarian cancer, appendiceal cancer	NCT02963831	I/II
Delta-24-RGD (DNX-2401)		Pembrolizumab	Glioblastoma, gliosarcoma	NCT02798406	II
LOAd703	CD40L, 4-1BBL	Gemcitabine, Nab-paclitaxel, atezolizumab	Pancreatic cancer	NCT02705196	I/II
		Atezolizumab	Melanoma	NCT04123470	I/II
VCN-01 (Ad-E2F-D24RGD-PH20)	PH-20	Durvalumab	Head and neck squamous cell carcinoma	NCT03799744	I
OBP-301		Pembrolizumab	Advanced solid tumor	NCT03172819	I
		Pembrolizumab	Esophagogastric adenocarcinoma	NCT03921021	II
CG0070	GM-CSF	Pembrolizumab	Non-muscle invasive bladder cancer	NCT04387461	II
Ad-MAGEA3	MAGE-A3	MG1-MAGEA3, pembrolizumab	Non-small-cell lung cancer	NCT02879760	I/II